Primary end point, all recorded coronary ischemic events, myocardial infarction, and bleeding events according to PlAgenotype, showing the number of events by genotype and percent of genotype that had events, according to the treatment groups
| Event . | Placebo (n = 353) . | Orbofiban 50/30 mg (n = 353) . | Orbofiban 50/50 mg (n = 308) . |
|---|---|---|---|
| Primary endpoint | |||
| PlA2 carriers (%) | 15 (15.5) | 24 (24.0) | 11 (15.7) |
| PlA2 noncarriers (%) | 48 (18.8) | 35 (13.8) | 32 (13.5) |
| Myocardial infarction | |||
| PlA2 carriers (%) | 3 (3.1) | 10 (10.0) | 3 (4.3) |
| PlA2 noncarriers (%) | 8 (3.1) | 4 (1.6) | 5 (2.1) |
| Bleeding | |||
| PlA2 carriers (%) | 15 (15.5) | 16 (16.0) | 9 (12.9) |
| PlA2 noncarriers (%) | 34 (13.3) | 48 (19.0) | 65 (27.3) |
| Event . | Placebo (n = 353) . | Orbofiban 50/30 mg (n = 353) . | Orbofiban 50/50 mg (n = 308) . |
|---|---|---|---|
| Primary endpoint | |||
| PlA2 carriers (%) | 15 (15.5) | 24 (24.0) | 11 (15.7) |
| PlA2 noncarriers (%) | 48 (18.8) | 35 (13.8) | 32 (13.5) |
| Myocardial infarction | |||
| PlA2 carriers (%) | 3 (3.1) | 10 (10.0) | 3 (4.3) |
| PlA2 noncarriers (%) | 8 (3.1) | 4 (1.6) | 5 (2.1) |
| Bleeding | |||
| PlA2 carriers (%) | 15 (15.5) | 16 (16.0) | 9 (12.9) |
| PlA2 noncarriers (%) | 34 (13.3) | 48 (19.0) | 65 (27.3) |
Carrier is PlA2/A2 or PlA1/A2 and PlA2 noncarrier is PlA1/A1.